ANI PHARMACEUTICALS INCANIPEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ANIP Q3 2025 Key Financial Metrics
Revenue
$227.8M
Gross Profit
N/A
Operating Profit
$36.2M
Net Profit
$26.6M
Gross Margin
N/A
Operating Margin
15.9%
Net Margin
11.7%
YoY Growth
53.6%
EPS
$1.13
Financial Flow
ANI PHARMACEUTICALS INC Q3 2025 Financial Summary
ANI PHARMACEUTICALS INC reported revenue of $227.8M for Q3 2025, with a net profit of $26.6M (11.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $227.8M |
|---|---|
| Net Profit | $26.6M |
| Gross Margin | N/A |
| Operating Margin | 15.9% |
| Report Period | Q3 2025 |
ANI PHARMACEUTICALS INC Annual Revenue by Year
ANI PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $614.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $614.4M |
| 2023 | $486.8M |
| 2022 | $316.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $131.7M | $137.4M | $138.0M | $148.3M | $190.6M | $197.1M | $211.4M | $227.8M |
| YoY Growth | 39.7% | 28.7% | 18.4% | 12.5% | 44.8% | 43.4% | 53.1% | 53.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $904.4M | $914.5M | $920.8M | $1.29B | $1.28B | $1.29B | $1.34B | $1.41B |
| Liabilities | $446.8M | $437.7M | $440.1M | $856.6M | $855.2M | $849.0M | $881.4M | $902.3M |
| Equity | $432.7M | $452.0M | $455.8M | $405.9M | $403.7M | $418.6M | $436.8M | $505.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $44.7M | $18.3M | $17.4M | $12.5M | $15.9M | $35.0M | $75.8M | $44.1M |